PCM
NMTR

Perkins Capital Management’s 9 Meters Biopharma NMTR Stock Holding History

Perkins Capital Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,500
Closed -$410K – 109
2021
Q1 		$410K Buy
17,500
+2,500
+17% +$76.8K 0.24% 83
2020
Q4 		$258K Buy
+15,000
New +$250K 0.17% 80

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perkins Capital Management's NMTR Position: Q2 2021 in Review

Perkins Capital Management sold out of 9 Meters Biopharma (NMTR) in Q2 2021, closing a stake of 17,500 shares — an estimated $410K sold.

Perkins Capital Management first reported a position in NMTR in Q4 2020 and held it in 2 quarters. The position peaked at $410K in Q1 2021. 99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

  • Perkins Capital Management reported no remaining 9 Meters Biopharma position as of Q2 2021 after selling out during the quarter.
  • Perkins Capital Management sold 17,500 9 Meters Biopharma shares in Q2 2021, an estimated $410K.
  • Perkins Capital Management first reported a position in 9 Meters Biopharma in Q4 2020 and held it in 2 quarters.
  • Perkins Capital Management's 9 Meters Biopharma position peaked at $410K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on Perkins Capital Management's 13F filing for Q2 2021, filed 28 Jul 2021.